Testing changed timing of spinal chemotherapy with blinatumomab for acute lymphoblastic leukemia
Tests methotrexate given into the spine with blinatumomab in adults with leukemia.
Key facts
- Who runs it
- Northside Hospital, Inc.
- Where
- Atlanta, United StatesSee the site
- Trial code
- Registry title
- Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 30 Jun 2023
- Expected to end
- 1 Jun 2027
- Type of study
- Interventional
- Treatments tested
- Methotrexate
- Blinatumomab
- Record updated
- 14 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with B-cell acute lymphoblastic leukemia that came back, did not respond to treatment, or still shows leftover disease (MRD-positive). They are about to start their first cycle of blinatumomab.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- B-cell acute lymphoblastic leukemia that is relapsed, refractory or MRD-positive
- Earlier treatment
- Must be receiving the first cycle of blinatumomab. People who had blinatumomab before cannot join.
- Biomarker or test result
- Negative for HIV. A negative serum pregnancy test, if applicable.
Main reasons for not taking part
- Active leukemia in the brain or spinal fluid (CNS involvement)
- Certain brain or nerve conditions, such as seizure, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's, cerebellar disease, psychosis, or coordination or movement disorder
- Cannot receive intrathecal methotrexate
- Prior treatment with blinatumomab
- Another active cancer besides ALL
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Adults receiving first cycle of blinatumomab for relapse/refractory or MRD-positive B-cell Acute Lymphoblastic Leukemia
- Adequate renal and hepatic function
- Negative for HIV
- Negative serum pregnancy test, if applicable
- ECOG 0-2
Who cannot take part
- Prior treatment with blinatumomab
- Active infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator
- Relative CNS disorders (seizure, paresis, aphasia, Cerebrovascular ischemia/hemorrhage, severe brain injury, dementia, Parkinson's, cerebellar disease, psychosis, coordination or movement disorder)
- Active malignancy other than ALL
- Active CNS involvement by ALL
- Contraindication to receive intrathecal methotrexate
Where in United States
- Northside HospitalAtlanta, United StatesContact: Caitlin Guzowski, MBA, MHATaking people
About the trial
What the trial wants to find out
Changing the schedule of intrathecal chemotherapy to be given before and during blinatumomab will maintain the anti-leukemic effects of this drug while at the same time adding the benefit of limiting the neurotoxicity associated with cytokine release.
The group in the trial
- Intrathecal chemotherapy before blinatumomabTreatment being tested
Treatment: Methotrexate and Blinatumomab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
- Plain-language title
- Testing changed timing of spinal chemotherapy with blinatumomab for acute lymphoblastic leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 14 October 2026